EXCLUSIVE: Expect Amarin FAQ Shortly; Some Speculate Drug Data Increase Acquisition Likelihood

Traders should expect an FAQ posted to Amarin's website within an hour, a company spokesperson commented to Benzinga. Industry sources, who wish to remain anonymous, commented to Benzinga that a data release out earlier this morning release may indicate Amarin's drug will be effective for a mass market. These sources commented that this makes the company more likely to be acquired because large heart disease makers can couple Amarin's technology with their existing drugs (which there are currently generics for). Amarin's release is expected to add insight to an earlier announcement on drug data titled, "EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at Approximately Twice the Prevalence Compared to Statin Therapy Alone in Japanese Clinical Study." The data shows that Vascepa (to lower triglycerides) combined with statins (to lower cholesterol) can reduce coronary heart disease risk. Shares of Amarin have traded in a large range this morning. The stock made a high of $2.30 and last traded at $2.12, up four percent on the day.